OA12244A - Oxazole derivatives and their uses as tyrosine kinase inhibitors. - Google Patents

Oxazole derivatives and their uses as tyrosine kinase inhibitors. Download PDF

Info

Publication number
OA12244A
OA12244A OA1200200311A OA1200200311A OA12244A OA 12244 A OA12244 A OA 12244A OA 1200200311 A OA1200200311 A OA 1200200311A OA 1200200311 A OA1200200311 A OA 1200200311A OA 12244 A OA12244 A OA 12244A
Authority
OA
OAPI
Prior art keywords
compound
sait
formula
cancer
agent
Prior art date
Application number
OA1200200311A
Other languages
English (en)
Inventor
Takenori Hitaka
Etsuya Matsutani
Akihiro Tasaka
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of OA12244A publication Critical patent/OA12244A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
OA1200200311A 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors. OA12244A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000106836 2000-04-07

Publications (1)

Publication Number Publication Date
OA12244A true OA12244A (en) 2006-05-10

Family

ID=18619943

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200311A OA12244A (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors.

Country Status (19)

Country Link
US (2) US6716863B2 (et)
EP (1) EP1268473A1 (et)
KR (1) KR20020028865A (et)
CN (1) CN1444582A (et)
AU (1) AU2001244726A1 (et)
BR (1) BR0109851A (et)
CA (1) CA2404760A1 (et)
CO (1) CO5261589A1 (et)
CZ (1) CZ20023264A3 (et)
EE (1) EE200200576A (et)
HU (1) HUP0300434A3 (et)
IL (1) IL152115A0 (et)
MX (1) MXPA02009621A (et)
NO (1) NO20024742L (et)
OA (1) OA12244A (et)
PE (1) PE20011178A1 (et)
PL (1) PL365787A1 (et)
SK (1) SK14132002A3 (et)
WO (1) WO2001077107A1 (et)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6004999A (en) * 1998-10-08 2000-04-26 Takeda Chemical Industries Ltd. Agents for retarding change of hormone-dependent cancer into hormone-independentcancer
EP1310491A1 (en) * 2000-07-19 2003-05-14 Takeda Chemical Industries, Ltd. Method for producing 1-substituted-1,2,3-triazole derivative
WO2002087616A1 (fr) * 2001-04-25 2002-11-07 Takeda Chemical Industries, Ltd. Remedes contre la recurrence postoperative du cancer du sein chez les femmes en premenopause
WO2002087618A1 (fr) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
US20040138160A1 (en) * 2001-04-27 2004-07-15 Kenichiro Naito Preventive/therapeutic method for cancer
CA2458452C (en) * 2001-08-10 2011-04-19 Takeda Chemical Industries, Ltd. Gnrh agonist combination drugs
US6984653B2 (en) * 2001-10-05 2006-01-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
WO2003041739A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticaner agents
EP1460067A4 (en) * 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVE, PROCESS FOR PRODUCTION OF THE DERIVATIVE, AND USE THEREOF
AU2003203170A1 (en) * 2002-01-17 2003-07-30 Takeda Chemical Industries, Ltd. Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
CA2483449A1 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
EP2402010A1 (en) * 2002-12-16 2012-01-04 Kissei Pharmaceutical Co., Ltd. Solid drug for oral use
TW200505913A (en) * 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
TW200423931A (en) * 2003-04-30 2004-11-16 Hoffmann La Roche Novel aniline derivatives, their manufacture and use as pharmaceutical agents
US7247649B2 (en) * 2003-08-13 2007-07-24 Hoffmann-La Roche Inc. Oxazoles, their manufacture and use as pharmaceutical agents
US7259262B2 (en) * 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents
US20050186275A1 (en) * 2004-02-23 2005-08-25 Standard Chem. & Pharm. Co. Ltd. Sustained release tamsulosin formulations
TW200612914A (en) 2004-03-05 2006-05-01 Hoffmann La Roche Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200533346A (en) 2004-03-18 2005-10-16 Hoffmann La Roche Novel ether derivatives, their manufacture and use as pharmaceutical agents
EP1737846A1 (en) 2004-04-02 2007-01-03 F.Hoffmann-La Roche Ag New process for the preparation of diazine derivatives
US7005526B2 (en) * 2004-05-25 2006-02-28 Hoffmann-La Roche Inc. Thioether derivatives
US7163953B2 (en) 2004-05-25 2007-01-16 Hoffmann-La Roche Inc. Benzylether derivatives
US7618769B2 (en) * 2004-06-07 2009-11-17 Applied Materials, Inc. Textured chamber surface
US7288557B2 (en) 2004-09-21 2007-10-30 Hoffmann-La Roche Inc. Triazole derivatives
TW200616951A (en) * 2004-09-22 2006-06-01 Hoffmann La Roche Indole derivatives, their manufacture and use as pharmaceutial agents
US20060069095A1 (en) * 2004-09-24 2006-03-30 Thomas Hofmeister Azole derivatives
US20060116407A1 (en) * 2004-11-22 2006-06-01 Birgit Bossenmaier Amide derivatives
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
TW200738680A (en) * 2005-08-04 2007-10-16 Hoffmann La Roche Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents
EP1915370A1 (en) * 2005-08-08 2008-04-30 F.Hoffmann-La Roche Ag Pyrazole derivatives, their manufacture and their use as pharmaceutical agents
CA2622944A1 (en) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Diazine azole derivatives, their manufacture and use as pharmaceutical agents
WO2008034579A1 (en) * 2006-09-20 2008-03-27 F. Hoffmann-La Roche Ag 2-heterocyclyl-5-phenoxymethylpyridine derivatives as anticancer agents
RU2009126576A (ru) 2006-12-12 2011-01-20 Такеда Фармасьютикал Компани Лимитед (Jp) Конденсированное гетероциклическое соединение
JP5328643B2 (ja) 2007-04-20 2013-10-30 大同化成工業株式会社 新規乾式固体分散体用基剤、該基剤を含有する固体分散体及び該分散体を含有する組成物
US20090233937A1 (en) 2008-03-12 2009-09-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
AR073679A1 (es) * 2008-09-26 2010-11-24 Takeda Pharmaceutical Prevencion y tratamiento de cancer con la no expresion de lkb1 supresion o mutacion, composicion farmaceutica. usos
WO2010036917A1 (en) * 2008-09-26 2010-04-01 Takeda Pharmaceutical Company Limited Prevention and treatment of cancer with ras gene mutation
KR101442069B1 (ko) 2009-09-30 2014-09-18 가부시키가이샤 상기 난용성 물질의 수용해성 개선방법
JP5705206B2 (ja) 2010-02-26 2015-04-22 日新化成株式会社 硬カプセルおよびその製造方法
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
JP5909796B2 (ja) 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
WO2014050910A1 (ja) 2012-09-26 2014-04-03 武田薬品工業株式会社 固体粒子の製造方法
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
ES2882255T3 (es) 2015-07-01 2021-12-01 California Inst Of Techn Sistemas de administración basados en polímeros de ácido múcico catiónicos
EP3238711B1 (en) 2016-04-26 2023-07-12 Mitsubishi Chemical Corporation Base for solid dispersion, production method for solid dispersion using same, and solid dispersion
CA2995617A1 (en) * 2017-11-03 2019-05-03 Universite De Montreal Heterocyclic mitochondrial activity inhibitors and uses thereof
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
CN114217025B (zh) * 2021-12-17 2024-01-23 哈尔滨工业大学 评估空气质量浓度预测中气象数据对其影响的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525109A4 (en) * 1990-04-16 1993-06-30 Rhone-Poulenc Rorer International (Holdings) Inc. Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase
WO1998003505A2 (en) 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use

Also Published As

Publication number Publication date
CO5261589A1 (es) 2003-03-31
CN1444582A (zh) 2003-09-24
EP1268473A1 (en) 2003-01-02
EE200200576A (et) 2004-06-15
SK14132002A3 (sk) 2003-04-01
MXPA02009621A (es) 2003-05-14
US6716863B2 (en) 2004-04-06
WO2001077107A1 (en) 2001-10-18
NO20024742D0 (no) 2002-10-02
KR20020028865A (ko) 2002-04-17
US20040024035A1 (en) 2004-02-05
HUP0300434A2 (hu) 2003-06-28
WO2001077107B1 (en) 2001-12-20
PE20011178A1 (es) 2001-11-19
PL365787A1 (en) 2005-01-10
CA2404760A1 (en) 2001-10-18
IL152115A0 (en) 2003-05-29
US20020173526A1 (en) 2002-11-21
WO2001077107A8 (en) 2003-02-13
HUP0300434A3 (en) 2004-11-29
AU2001244726A1 (en) 2001-10-23
BR0109851A (pt) 2003-06-03
CZ20023264A3 (cs) 2003-02-12
NO20024742L (no) 2002-11-25

Similar Documents

Publication Publication Date Title
OA12244A (en) Oxazole derivatives and their uses as tyrosine kinase inhibitors.
US6984653B2 (en) Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
US10736883B2 (en) Triazole furan compounds as agonists of the APJ receptor
US6852734B2 (en) Indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof
US6743924B2 (en) Method for producing 1-substituted-1,2,3-triazole derivative
US11111230B2 (en) Indoleamine 2,3-dioxygenase inhibitors and use of same in medicine
US20220073476A1 (en) Triazole compounds and preparation method therefor and use thereof
JP3273777B2 (ja) 複素環化合物、その製造法および用途
KR102640385B1 (ko) 고혈압 및/또는 폐 섬유증 치료용 조성물
JP2003277379A (ja) 含窒素複素環化合物、その製造法および用途
EP1042277A1 (en) Naphthalene derivatives
JP2811577B2 (ja) 強心アルカノイル及びアロイルオキサゾロン類
JP2002069070A (ja) 複素環化合物、その製造法および用途
JP2004161660A (ja) リウマチ予防・治療剤
US11945811B2 (en) Potassium channel inhibitors
JP2003176287A (ja) 複素環化合物オキサゾール誘導体、その製造法および用途
JP2005035944A (ja) スチレン誘導体、その製造法および用途
JP2003048882A (ja) １−置換−１，２，３−トリアゾール誘導体の製造方法
FR2855520A1 (fr) Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament